Julia Elisa Sepúlveda Díaz

Julia Elisa Sepúlveda Díaz

Auto-generated profile, based on publicly available information

Julia Elisa Sepúlveda Díaz

Institut National de la Santé et de la Recherche Médicale, U 1127, CNRS, Unité Mixte de Recherche (UMR) 7225, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2018 in Glia
Verified
Journal Article
Open access
PDF file
FMFrançois Mouton‐Liger
François Mouton‐Liger
TRThibault Rosazza
Thibault Rosazza
JSJulia Sepulveda‐Diaz
Julia Sepulveda‐Diaz
AIAmélie Ieang
Amélie Ieang
SHSidi‐Mohamed Hassoun
Sidi‐Mohamed Hassoun
OCOlga Corti
Olga Corti
Neuroinflammation and mitochondrial dysfunction, key mechanisms in the pathogenesis of Parkinson's disease (PD), are usually explored independently. Loss‐of‐function mutations of PARK2 and PARK6, encoding the E3 ubiquitin protein ligase Parkin and the mitochondrial serine/threonine kinase PINK1, account for a large proportion of cases of autosomal recessive early‐onset PD. PINK1 and Parkin regulate mitochondrial quality control and have been linked to the modulation of innate immunity pathways. We report here an exacerbation of NLRP3 inflammasome activation by specific inducers in microglia and bone marrow‐derived macrophages from Park2−/− and Pink1−/− mice. The caspase 1‐dependent release of IL‐1β and IL‐18 was, therefore, enhanced in Park2−/− and Pink1−/− cells. This defect was confirmed in blood‐derived macrophages from patients with PARK2 mutations and was reversed by MCC950, which specifically inhibits NLRP3 inflammasome complex formation. Enhanced NLRP3 signaling in Parkin‐deficient cells was accompanied by a lack of induction of A20, a well‐known negative regulator of the NF‐κB pathway recently shown to attenuate NLRP3 inflammasome activity. We also found an inverse correlation between A20 abundance and IL‐1β release, in human macrophages challenged with NLRP3 inflammasome inducers. Overall, our observations suggest that the A20/NLRP3‐inflammasome axis participates in the pathogenesis of PARK2‐linked PD, paving the way for the exploration of its potential as a biomarker and treatment target.

8 January 2016 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
FSFlávia V. Santa-Cecília
Flávia V. Santa-Cecília
BSBenjamin Socias
Benjamin Socias
MOMohand O. Ouidja
Mohand O. Ouidja
JSJulia E. Sepulveda-Diaz
Julia E. Sepulveda-Diaz
LALeonardo Acuña
Leonardo Acuña
Rita Raisman-VozariRita Raisman-Vozari
Rita Raisman-Vozari

4 April 2015 in Brain
Verified
Journal Article
Open access
PDF file
JSJulia Elisa Sepulveda-Diaz
Julia Elisa Sepulveda-Diaz
SNSeyedeh Maryam Alavi Naini
Seyedeh Maryam Alavi Naini
MHMinh Bao Huynh
Minh Bao Huynh
MOMohand Ouidir Ouidja
Mohand Ouidir Ouidja
CYConstantin Yanicostas
Constantin Yanicostas
DPDulce Papy-García
Dulce Papy-García
Heparan sulphate (glucosamine) 3-O-sulphotransferase 2 (HS3ST2, also known as 3OST2) is an enzyme predominantly expressed in neurons wherein it generates rare 3-O-sulphated domains of unknown functions in heparan sulphates. In Alzheimer’s disease, heparan sulphates accumulate at the intracellular level in disease neurons where they co-localize with the neurofibrillary pathology, while they persist at the neuronal cell membrane in normal brain. However, it is unknown whether HS3ST2 and its 3-O-sulphated heparan sulphate products are involved in the mechanisms leading to the abnormal phosphorylation of tau in Alzheimer’s disease and related tauopathies. Here, we first measured the transcript levels of all human heparan sulphate sulphotransferases in hippocampus of Alzheimer’s disease (n = 8; 76.8 ± 3.5 years old) and found increased expression of HS3ST2 (P < 0.001) compared with control brain (n = 8; 67.8 ± 2.9 years old). Then, to investigate whether the membrane-associated 3-O-sulphated heparan sulphates translocate to the intracellular level under pathological conditions, we used two cell models of tauopathy in neuro-differentiated SH-SY5Y cells: a tau mutation-dependent model in cells expressing human tau carrying the P301L mutation hTauP301L, and a tau mutation-independent model in where tau hyperphosphorylation is induced by oxidative stress. Confocal microscopy, fluorescence resonance energy transfer, and western blot analyses showed that 3-O-sulphated heparan sulphates can be internalized into cells where they interact with tau, promoting its abnormal phosphorylation, but not that of p38 or NF-κB p65. We showed, in vitro, that the 3-O-sulphated heparan sulphates bind to tau, but not to GSK3B, protein kinase A or protein phosphatase 2, inducing its abnormal phosphorylation. Finally, we demonstrated in a zebrafish model of tauopathy expressing the hTauP301L, that inhibiting hs3st2 (also known as 3ost2) expression results in a strong inhibition of the abnormally phosphorylated tau epitopes in brain and in spinal cord, leading to a complete recovery of motor neuronal axons length (n = 25; P < 0.005) and of the animal motor response to touching stimuli (n = 150; P < 0.005). Our findings indicate that HS3ST2 centrally participates to the molecular mechanisms leading the abnormal phosphorylation of tau. By interacting with tau at the intracellular level, the 3-O-sulphated heparan sulphates produced by HS3ST2 might act as molecular chaperones allowing the abnormal phosphorylation of tau. We propose HS3ST2 as a novel therapeutic target for Alzheimer’s disease.

3 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FGFlorencia González-Lizárraga
Florencia González-Lizárraga
SSSergio B. Socías
Sergio B. Socías
CÁCésar L. Ávila
César L. Ávila
CTClarisa M. Torres-Bugeau
Clarisa M. Torres-Bugeau
LBLeandro R. S. Barbosa
Leandro R. S. Barbosa
RCRosana Chehin
Rosana Chehin
Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein we characterise novel targets of doxycycline describing the structural background supporting its effectiveness as a neuroprotector at subantibiotic doses. Our results show that doxycycline reshapes α-synuclein oligomers into off-pathway, high-molecular-weight species that do not evolve into fibrils. Off-pathway species present less hydrophobic surface than on-pathway oligomers and display different β-sheet structural arrangement. These structural changes affect the α-synuclein ability to destabilize biological membranes, cell viability, and formation of additional toxic species. Altogether, these mechanisms could act synergically giving novel targets for repurposing this drug.

1 November 2018 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
ASAndreza B. Sonego
Andreza B. Sonego
DPDouglas S. Prado
Douglas S. Prado
GVGabriel T. Vale
Gabriel T. Vale
JSJulia E. Sepulveda-Diaz
Julia E. Sepulveda-Diaz
TCThiago M. Cunha
Thiago M. Cunha
FGFrancisco S. Guimarães
Francisco S. Guimarães

25 July 2019 in Cells
Verified
Journal Article
Open access
PDF file
LALeonardo Acuña
Leonardo Acuña
SHSabah Hamadat
Sabah Hamadat
NCNatalia Soledad Corbalán
Natalia Soledad Corbalán
FGFlorencia González-Lizárraga
Florencia González-Lizárraga
MDMauricio Dos-Santos-Pereira
Mauricio Dos-Santos-Pereira
Rita Raisman-VozariRita Raisman-Vozari
Rita Raisman-Vozari
Aggregated forms of the synaptic protein α-synuclein (αS) have been proposed to operate as a molecular trigger for microglial inflammatory processes and neurodegeneration in Parkinson´s disease. Here, we used brain microglial cell cultures activated by fibrillary forms of recombinant human αS to assess the anti-inflammatory and neuroprotective activities of the antibiotic rifampicin (Rif) and its autoxidation product rifampicin quinone (RifQ). Pretreatments with Rif and RifQ reduced the secretion of prototypical inflammatory cytokines (TNF-α, IL-6) and the burst of oxidative stress in microglial cells activated with αS fibrillary aggregates. Note, however, that RifQ was constantly more efficacious than its parent compound in reducing microglial activation. We also established that the suppressive effects of Rif and RifQ on cytokine release was probably due to inhibition of both PI3K- and non-PI3K-dependent signaling events. The control of oxidative stress appeared, however, essentially dependent on PI3K inhibition. Of interest, we also showed that RifQ was more efficient than Rif in protecting neuronal cells from toxic factors secreted by microglia activated by αS fibrils. Overall, data with RifQ are promising enough to justify further studies to confirm the potential of this compound as an anti-parkinsionian drug.